◎ Sugi Atlas

Atlas / Drug / Itraconazole

Itraconazole

drug
On this page

Also known as CandistatCanditralCladosal 100FungitraxxItracItraconazolItraconazole component of suba-ItralekItrizoleNSC-759239OrungalR 51,211R-51211SemperaSpherazole crSpherazole irSporameltSporanoxSporanox i.v.

Summary

Itraconazole (CHEMBL64391) is an approved small molecule (ATC J02AC02); indicated across 69 conditions including blastomycosis and aspergillosis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: J02AC02
  • Indications: 69 conditions
  • Clinical trials: 423
  • Chemistry: 705.6 Da · C35H38Cl2N8O4

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL64391
NameItraconazole
TypeSmall molecule
Max phase4
FDA approvedno
PubChem CID3793
ATCJ02AC02
Molecular formulaC35H38Cl2N8O4
Molecular weight705.6
InChIKeyVHVPQPYKVGDNFY-UHFFFAOYSA-N

SMILES: CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl

IUPAC name: 2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one

Also known as: Candistat, Canditral, Cladosal 100, Fungitraxx, Itrac, Itraconazol, Itraconazole, Itraconazole component of suba-, Itralek, Itrizole, NSC-759239, Orungal

Parent form; salt/anhydrous children: CHEMBL5483033

Patent coverage: 268 distinct patent families (606 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 525 (87%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 21 (assay-derived). Sample: Microtubule-associated protein tau, Prelamin-A/C, Sterol 14-alpha demethylase cyp51A, Vasopressin V2 receptor, Tyrosine-protein kinase Fyn, Menin/Histone-lysine N-methyltransferase MLL, C-C chemokine receptor type 4, Substance-P receptor, ATP-dependent translocase ABCB1, 3’,5’-cyclic-AMP phosphodiesterase 4D.

Bioactivity

ChEMBL activities: 47 potent at pChembl ≥ 5 of 57 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
ABCB17.52IC5030nMCHEMBL_ACT_1170220
CYP3A47.49IC5032.6nMCHEMBL_ACT_16828761
CYP3A47.49IC5032.6nMCHEMBL_ACT_23308589
CYP3A47.4IC5040nMCHEMBL_ACT_18951848
CYP3A47.3IC5050.4nMCHEMBL_ACT_16595992
CYP3A47.16IC5070nMCHEMBL_ACT_15010492
CXCR17IC50100nMCHEMBL_ACT_12654649
CXCR16.8IC50158.5nMCHEMBL_ACT_12654650
P214476.7IC50200nMCHEMBL_ACT_11000856
P214476.7IC50200nMCHEMBL_ACT_1170221
CCR46.7IC50200nMCHEMBL_ACT_12653375
CCR46.3IC50500nMCHEMBL_ACT_12654670
CCR46.3IC50501.2nMCHEMBL_ACT_12654671
MEN16.2Potency631nMCHEMBL_ACT_4565640
ABCB116.18AC50660nMCHEMBL_ACT_25126992
P067956.16IC50700nMCHEMBL_ACT_11000884
CYP3A46.16IC50700nMCHEMBL_ACT_1170217
P067956.16IC50700nMCHEMBL_ACT_1170222
AVPR26.1IC50800nMCHEMBL_ACT_12654627
AVPR26.1IC50794.3nMCHEMBL_ACT_12654628
CYP3A46.05IC50900nMCHEMBL_ACT_7752597
Q4WNT56Kd1010nMCHEMBL_ACT_5229869
MAPT5.85Potency1412nMCHEMBL_ACT_4039288
TACR15.81AC501543nMCHEMBL_ACT_25128740
ABCB15.77IC501700nMCHEMBL_ACT_11000927
ABCG25.7IC502000nMCHEMBL_ACT_24777410
MAPT5.7Potency1995nMCHEMBL_ACT_4041563
ABCB15.68IC502100nMCHEMBL_ACT_11001301
ABCB15.68IC502100nMCHEMBL_ACT_1170223
ABCB15.62IC502400nMCHEMBL_ACT_11001313

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

69 indications (7 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
blastomycosis4MONDO:0005672EFO:0007174
aspergillosis4MONDO:0005657EFO:0007157
candidiasis4MONDO:0002026MONDO:0002026
fungal infectious disease4MONDO:0002041MONDO:0002041
lung disorder4MONDO:0005275EFO:0003818
tinea infection4MONDO:0005982EFO:0007510
tinea unguium4MONDO:0001628MONDO:0001628
neoplasm3MONDO:0005070EFO:0000616
allergic bronchopulmonary aspergillosis3MONDO:0015243EFO:0007140
histoplasmosis3MONDO:0018312EFO:0007310
cryptococcosis3MONDO:0005724EFO:0007229
bronchiectasis3MONDO:0004822HP:0002110
sinusitis2MONDO:0005961EFO:0007486
prostate adenocarcinoma2MONDO:0005082EFO:0000673
basal cell carcinoma2MONDO:0020804EFO:0004193
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
acute myeloid leukemia2MONDO:0018874EFO:0000222
Cryptococcal meningitis2MONDO:0005723EFO:0007228
eumycotic mycetoma2MONDO:0005757EFO:0007265
hematologic disorder2MONDO:0005570HP:0001871
tinea pedis2MONDO:0005984EFO:0007512
pityriasis versicolor2MONDO:0005915EFO:0007439
burn2MONDO:0043519EFO:0009516
ovarian cancer2MONDO:0008170MONDO:0008170
lung neoplasm2MONDO:0021117MONDO:0008903
coccidioidomycosis2MONDO:0005706EFO:0007211
Crohn disease2MONDO:0005011EFO:0000384
opiate dependence2MONDO:0005530EFO:0010702
skin neoplasm2MONDO:0002531MONDO:0002898
neuralgia1MONDO:0021667EFO:0005762
chronic hepatitis C virus infection1MONDO:0005354EFO:0004220
myelodysplastic syndrome1MONDO:0018881EFO:0000198
chronic obstructive pulmonary disease1MONDO:0005002EFO:0000341
glioblastoma1MONDO:0018177EFO:0000519
lymphoma1MONDO:0005062EFO:0000574
polycystic ovary syndrome1MONDO:0008487EFO:0000660
plasma cell myeloma1MONDO:0009693EFO:0001378
metastatic melanoma1MONDO:0005191EFO:0002617
sporotrichosis1MONDO:0005968EFO:0007494
heart failure1MONDO:0005252EFO:0003144
inflammatory bowel disease1MONDO:0005265EFO:0003767
respiratory syncytial virus infectious disease1MONDO:0001577EFO:1001413
chronic hepatitis B virus infection1MONDO:0005366EFO:0004239
thrombotic disease1MONDO:0000831MONDO:0000831
hepatitis B virus infection1MONDO:0005344EFO:0004197
severe acute respiratory syndrome1MONDO:0005091MONDO:0100096
celiac disease1MONDO:0005130EFO:0001060
malaria1MONDO:0005136EFO:0001068
non-Hodgkin lymphoma1MONDO:0018908EFO:0005952
Alzheimer disease1MONDO:0004975MONDO:0004975
asthma1MONDO:0004979MONDO:0004979
cystic fibrosis1MONDO:0009061MONDO:0009061
bacterial infectious disease1MONDO:0005113EFO:0000771
amyotrophic lateral sclerosis1MONDO:0004976MONDO:0004976
obesity disorder1MONDO:0011122EFO:0001073
chronic kidney disease1MONDO:0005300EFO:0003884
erectile dysfunction1MONDO:0005362EFO:0004234
anti-neutrophil antibody associated vasculitis1MONDO:0005435EFO:0004826
spinal muscular atrophy1MONDO:0001516MONDO:0019079
primary myelofibrosis1MONDO:0009692MONDO:0044903

9 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 423.

Phase distribution

PhaseTrials
PHASE1324
PHASE224
Not specified23
PHASE416
PHASE1/PHASE212
PHASE311
PHASE2/PHASE37
EARLY_PHASE16

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06922344PHASE4RECRUITINGComparison of Efficacy of Oral Fluconazole Versus Oral Itraconazole in the Treatment of Pityriasis Versicolor
NCT07283497PHASE4RECRUITINGItraconazole Therapy In Bronchiectasis With Airway Mold
NCT07342153PHASE4RECRUITINGComparing the Efficacy of Oral Fluconazole Versus Oral Itraconazole in Treating Resistant Tinea Corporis
NCT00336531PHASE4COMPLETEDEfficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
NCT00528190PHASE4COMPLETEDTreatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis
NCT00787917PHASE4TERMINATEDAn Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
NCT00871728PHASE4COMPLETEDScoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules
NCT01198236PHASE4COMPLETEDEfficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection
NCT01214941PHASE4COMPLETEDEffect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol
NCT01259336PHASE4COMPLETEDEfficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis
NCT01282879PHASE4TERMINATEDEvaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients
NCT01823289PHASE4COMPLETEDAn Efficacy and Safety Study of Itraconazole Sequential Therapy (Intravenous Injection Followed by Oral Solution) in Invasive Pulmonary Fungal Infections
NCT02621905PHASE4COMPLETEDSteady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg
NCT02895529PHASE4TERMINATEDA Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy
NCT03923010PHASE4TERMINATEDA Study of Itraconazole in the Management of Superficial Fungal Infections in India
NCT04035187PHASE4COMPLETEDItraconazole Oral Absorption
NCT03458221PHASE2/PHASE3RECRUITINGSignal TrAnsduction Pathway Activity Analysis in OVarian cancER
NCT03656081PHASE3RECRUITINGChronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole
NCT06174922PHASE3RECRUITINGA Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis
NCT00002159PHASE3COMPLETEDA Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis
NCT00003883PHASE3COMPLETEDItraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
NCT00289991PHASE3COMPLETEDVoriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)
NCT00673309PHASE2/PHASE3COMPLETEDAssessment of Mechanisms of Improved Wound Healing
NCT00784368PHASE3COMPLETEDA Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection
NCT00794703PHASE3COMPLETEDA Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections
NCT01321827PHASE2/PHASE3COMPLETEDMonotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis
NCT02285283PHASE2/PHASE3TERMINATEDItraconazole for Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps
NCT02440009PHASE2/PHASE3COMPLETEDA Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis
NCT03572049PHASE2/PHASE3COMPLETEDEndemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole
NCT03920527PHASE3COMPLETEDSix Months Versus 12 Months of Oral Itraconazole Therapy for Management of Treatment naïve Subjects With CPA
NCT04824417PHASE3COMPLETEDA Randomized Controlled Trial to Compare the Clinical Outcomes With Six Months of Therapy With Oral Itraconazole Versus Oral Voriconazole for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis
NCT04880980PHASE3COMPLETEDComparison of Efficacy of Double Dose Oral Terbinafine Vs Itraconazole in Treatment of Dermatophyte Infections of Skin.
NCT05881980PHASE2/PHASE3UNKNOWNEfficacy and Safety of Terbinafine and Itraconazole
NCT06160713PHASE3UNKNOWNCompare Oral Itraconazole and Standard Care Versus Standard Care Alone in Patients With Non-cystic Fibrosis Related Bronchiectasis With Chronic Aspergillus Infection in Reducing Bronchiectasis Exacerbations
NCT04018872PHASE2RECRUITINGEvaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
NCT04067336PHASE1/PHASE2ACTIVE_NOT_RECRUITINGFirst in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT05150691PHASE1/PHASE2RECRUITINGA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05384626PHASE1/PHASE2RECRUITINGA Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT05563766PHASE2RECRUITINGA Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
NCT05914116PHASE1/PHASE2RECRUITINGA Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 17

This page pulls from 17 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_interactiongtopdb_ligandhgncmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchemuniprot